loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations
Open ICICI 3-in-1 Account

Glenmark Pharmaceuticals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Glenmark Pharmaceuticals Ltd. 14 Aug 2025 18:18 PM
Result PDF

Q1FY26 Quarterly Result Announced for Glenmark Pharmaceuticals Ltd.

Pharmaceuticals company Glenmark Pharmaceuticals announced Q1FY26 results

  • Consolidated revenue was Rs 32,644 million as against Rs 32,442 million, recording an increase of 0.6% YoY.
  • EBITDA was Rs 5,805 million in Q1FY26, as compared to Rs 5,607 million in Q1FY25, with an EBITDA margin of 17.8%.
  • Adjusted Profit After Tax (PAT) for Q1FY26 was at Rs 3,129 million, with an adjusted PAT margin of 9.6%.

Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals, said: “In Q1FY26, our U.S. business delivered QoQ growth, driven by a combination of injectable and partnered products launches. Our Europe and Emerging markets businesses have recorded >25% CAGR and >10% CAGR respectively over the last three years, and we expect the region to deliver a double-digit growth from the second quarter onwards. The recent IGI-AbbVie global licensing agreement for ISB 2001 is a strong validation of our innovation capabilities. We remain confident in our strategy to drive growth across our markets, while advancing our branded, speciality, and innovative products to deliver long-term value for our stakeholders.”

Result PDF

Result PDF

Glenmark Pharmaceuticals announced Q1FY24 results:

  • Europe Business grew by 73.7% to Rs 5,732 million.
  • ROW Business grew by 30.4% to Rs 5,512 million.
  • North America Business grew by 22% to Rs 8,085 million.
  • India's Business grew by 2.8% to Rs 10,643 million.
  • EBITDA of Rs 6,312 million grew by 46.2% YoY, with margins of 18.6%.
  • Consolidated revenue was at Rs 34,016 million as against Rs 27,773 million recording an increase of 22.5% YoY.
  • Profit After Tax (PAT) for Q1FY24 was at Rs 1,731 million.

“We had yet another strong quarter both in terms of revenue and operating margins. The robust growth in sales was led by our branded markets in the RoW region. Our Europe business performed significantly well on the back of a strong generics portfolio and continued gains in market share, in our leading respiratory brands. Our North American business remained stable, and our India business continued to significantly outperform industry growth rates. We also had our GHG emission targets certified by the Science Based Targets initiative (SBTi) giving us an impetus to further pursue our ESG goals, while also benchmarking us at a global scale.” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.

He further added, “Going forward our goal remains to sustain the momentum, as RYALTRIS continues to meaningfully contribute across all the covered markets. We also remain on track to achieve our objectives for FY24.”

 

 

Result PDF

Glenmark Pharmaceuticals announced Q4FY23 & FY23 results:

  • Q4FY23:
    • ROW Business grew by 25.1% YoY to Rs 6,856 million
    • Europe Business grew by 22.3% YoY to Rs 6,078 million
    • North America Business recorded growth of 15.3% YoY to Rs 8,507 million
    • India Business recorded a decline of 6.4% YoY to Rs 8,284 million
    • EBITDA was at Rs 6,050 million, with a margin of 17.9%
    • Consolidated revenue was at Rs 33,737 million vs Rs 30,191 million recording an increase of 11.7% YoY
    • EBITDA was Rs 6,050 million in Q4FY23, as compared to Rs 4,634 million in Q4FY22, registering growth of 30.5%. EBITDA margin for Q4FY23 was 17.9 %.
    • Reported net loss of Rs 4,031 million for Q4FY23 on account of an exceptional loss of Rs 7,997 million, primarily on account of the settlement of the litigation related to generic Zetia in the U.S.
  • FY23:
    • Consolidated revenue was at Rs 1,29,901 million as against Rs 1,23,049 million, recording an increase of 5.6 % over FY22
    • EBITDA for FY23 stood at Rs 22,784 million as against Rs 23,203 million in FY22
    • EBITDA margin for FY 2022-23 was at 17.5%
    • Net Profit (PAT) was at Rs 3,774 million for FY23, as against Rs 9,936 million in FY22. The PAT for FY23 was lower on account of an exceptional loss of Rs 7,659 million primarily on account of the settlement of the litigation related to generic Zetia in the U.S.

“We delivered yet another year of robust performance, despite the challenging global macro-economic environment. Our India business recorded double-digit growth in secondary sales. The North American business showed a strong recovery, and the EU and RoW markets did phenomenally well. We continued to make headway in launching Ryaltris®, our first globally branded specialty product. Additionally, we initiated the Proof-of-Concept studies for four of our clinical oncology assets, which are part of the Glenmark/Ichnos pipeline,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.

He further added, “We look forward to continue this momentum in the coming year with double-digit revenue growth and significant improvement in EBITDA margins.”

 

 

Result PDF

Glenmark Pharmaceuticals announced Q2FY23 results:

  • For Q2FY23, Glenmark’s consolidated revenue was at Rs 33,752 million as against Rs 31,474 million, recording an increase of 7.2%
  • Reported EBITDA was at Rs 6,216 million in Q2FY23, as against Rs 5,902 million in the previous corresponding quarter, with a margin of 18.4%, registering an increase of 5.3%
  • Adjusted EBITDA for the quarter was at Rs 6,526 million, with an adjusted EBITDA margin of 19.3%.
  • Profit after Tax (PAT) was at Rs 2,787 million for Q2FY23, as compared to Rs 2,748 million in the previous corresponding quarter, recording a growth of 1.4%.

“We delivered yet another quarter of consistent growth, with our relentless focus on launching differentiated products in our core therapeutic areas. Our novel drug Ryaltris™ was launched in the US by our partner Hikma, and our Canadian partner, Bausch Health, received marketing approval from Health Canada with an expected launch during the second half of the financial year. Our India business recorded strong double-digit growth and our Europe business also performed very well in spite of a challenging macro-economic environment,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd. He further added, “We look forward to launching new products across markets and building global scale in our respiratory portfolio. We remain focused in achieving our strategic objectives for the financial year.”

 

Result PDF

Glenmark Pharmaceuticals announced Q4FY22 results:

  • For the Q4FY22, Glenmark’s consolidated revenue was at Rs. 30,191 million as against Rs. 28,599 million recording an increase of 5.6 % YoY.
  • Adjusted EBITDA was Rs. 5,022 million in the quarter ended March 31, 2022, with margins of 16.6 %.
  • Reported EBITDA was Rs. 4,634 million in the quarter ended March 31, 2022, as compared to Rs. 5,234 million in the previous corresponding quarter with margins of 15.3%
  • Adjusted Net Profit (PAT) was at Rs. 2,939 million for the quarter ended March 31, 2022.
  • Reported PAT was at Rs. 1,726 million for the quarter ended March 31, 2022, as compared to Rs. 2,340 million in the previous corresponding quarter.
  • FY22 Glenmark’s consolidated revenue was at Rs. 123,049 million as against Rs. 1,09,439 million, recording an increase of 12.4 % over the previous corresponding period
  • Adjusted EBITDA for the fiscal year ended March 31, 2022, stood at Rs. 23,591 million.
  • Reported EBITDA for the fiscal year ended March 31, 2022 stood at Rs. 23,203 as against Rs. 20,844 million in the previous corresponding period.
  • Net Profit (PAT) was at Rs. 9,936 million. for the year ended March 31, 2022, as against Rs. 9,701 million. in the previous year.
  • Earnings Per Share (EPS) is at Rs. 33.4 as compared to Rs. 34.4 YoY basis.

“We delivered consistent performance throughout the year and achieved our key objectives, despite challenging global macro environment. We were able to successfully list Glenmark Lifesciences on the Indian Bourses. The out-licensing deal for ISB 880 with Almirall and US FDA approval for Ryaltris, further established us as the leading innovation-driven pharma company in the country.” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals. He added,”We are confident of growing our business with continuous emphasis on innovation, sustainability, and prioritizing free cash generation for additional debt reduction.”

 

 

Result PDF

Glenmark Pharmaceuticals declares Q3FY22 result:

  • Glenmark Pharma reports revenue growth of 13.9% and EBITDA growth of 30.8% YoY for Q3 FY 2021-22
  • India Business grew by 14.2% to Rs. 10,069 Mn.
  • ROW Business grew by 24.3% to Rs. 4,178 Mn.
  • Europe Business grew by 21.5% to Rs. 3,807 Mn.
  • EBITDA of Rs. 6,932 Mn grew by 30.8% YoY, with margins of 21.8%.
  • For the third quarter of FY 2021-22, Glenmark’s consolidated revenue was at Rs. 31,734 Mn as against Rs. 27,868 Mn recording an increase of 13.9% YoY.
  • Consolidated EBITDA was at Rs. 6,932 Mn in the quarter ended December 31, 2021 as against Rs. 5,301 Mn in the previous corresponding quarter, registering an increase of 30.8% YoY.

“We had a landmark quarter with strong performance and the achievement of some key milestones. We closed our eighth out-licensing deal in our innovation pipeline, establishing us as one of the leading innovation-driven pharma companies in the country. Our businesses have also maintained their good growth momentum.” said Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. He further added, “We are on track to achieve our key business objectives for the financial year.”

Result PDF

Highlights:

  • Glenmark Pharma reports revenue growth of 6.6% and PAT growth of 10.1% YoY for Q2 FY 2021-22
  • ROW Business grew by 71.5% to Rs. 6,526 Mn
  • Europe Business grew by 6.3% to Rs. 3,383 Mn
  • EBITDA of Rs. 5,902 Mn grew by 6.8% YoY, with margins of 18.8%.
  • For the second quarter of FY 2021-22, Glenmark’s consolidated revenue was at Rs. 31,474 Mn as against Rs. 29,525 Mn recording an increase of 6.6%.
  • Consolidated EBITDA was at Rs. 5,902 Mn in the quarter ended Sept 30, 2021 as against Rs. 5,699 Mn in the previous corresponding quarter, registering an increase of 6.8%.
  • Profit after Tax (PAT)1 was at Rs. 2,577 Mn for the quarter ended Sept 30, 2021 as compared to Rs. 2,340 Mn in the previous corresponding quarter, recording a growth of 10.1%.

“We delivered yet another quarter of consistent performance, both in revenue growth and profitability. We have continued to perform well in our core therapy areas and launched differentiated products.” said Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. He further added, “We have substantially reduced our debt through a combination of internal accruals and IPO proceeds. We are focused on enhancing free cash generation and achieving our strategic objectives going forward."

Result PDF

Highlights for Q1 FY 2021-22: 

  • Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY for Q1 FY 2021-22.
  • India Business grew by 57 % YoY to Rs. 12,250 Mn.
  • North America Business recorded growth of 6% YoY to Rs. 7,878 Mn.
  • Europe Business grew by 12% YoY to Rs. 3,059 Mn.
  • ROW Business grew by 27% YoY to Rs. 2,686 Mn.
  • API Business grew by 29% YoY to Rs. 3040 Mn.
  • EBITDA of Rs. 5,736 Mn grew by 20% YoY with margins of 19%.
  • For the First Quarter of FY 2021-22, Glenmark’s consolidated revenue was at Rs. 29,649 Mn. as against Rs. 23,448 Mn recording an increase of 26%
  • Consolidated EBITDA grew by 20% to Rs. 5,736 Mn in the quarter ended June 30, 2021 as against Rs. 4781 Mn. in the previous corresponding quarter.
  • Profit After Tax (PAT) was at Rs. 3,065 Mn for the quarter ended June 30, 2021 as compared to Rs. 2540 Mn in the previous corresponding quarter, registering an increase of 21% YoY.

“It was a landmark quarter for the company with positive momentum in all our key markets. Our commitment towards the fight against COVID19 was reflected in FabiFlu® becoming the number one brand in the India pharma market in April. We launched our first nebulizer, Arformoterol Inhalation solution from Monroe, US.” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals. He further added, “We have a strategic roadmap to grow consistently and profitably over the year. “We have a clear plan in place to reduce debt by enhancing free cash, prioritizing over R&D investments and capital expenditure going forward.”

Result PDF

Trending News

Nestle India adds 20,500 tonnes of Maggi capacity at Sanand facility

Nestle India has announced addition of 20,500 tonnes/annum of Maggi capacity at Sanand facility. 

Published on 02-Apr-2026 09:19

Power Grid wins transmission project for 2.7 GW of renewable energy capacity at Tumkur-II, Karnataka

Power Grid Corporation of India Limited (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding (TBCB) for a transmission project aimed at integrating 2.7 GW of additional renewable energy capacity at Tumkur-II, Karnataka. 

Published on 02-Apr-2026 09:18

Tata Power resumes operations at 4,150 MW Mundra thermal power plant

Tata Power Company Limited has resumed operations at its 4,150 MW Mundra thermal power plant in Gujarat from April 1, 2026, after a nine-month shutdown. 

Published on 02-Apr-2026 09:17

Indian Bank's gross advances grow 13.6% YoY to ₹6,680 lakh crore

Indian Bank reported steady business growth in Q4FY26 (provisional), with gross advances rising to ₹6.68 lakh crore, up 13.6% YoY (4.5% QoQ). 

Published on 02-Apr-2026 09:16

South Indian Bank's gross advances grow 15.7% YoY to ₹101,295 crore

South Indian Bank reported steady business growth in Q4FY26 (provisional), with gross advances rising to ₹1,01,295 crore, up 15.7% YoY (4.7% QoQ). 

Published on 02-Apr-2026 09:15

Karnataka Bank's gross advances grow 6.9% YoY to ₹83,336.9 crore

Karnataka Bank reported healthy sequential business growth in Q4FY26 (provisional), with gross advances rising to ₹83,336.9 crore, up 6.9% YoY (7.8% QoQ). 

Published on 02-Apr-2026 09:14

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app